US 10,647,762 B2Granted

Antibodies specific for hyperphosphorylated tau and methods of use thereof

AssigneeH. Lundbeck A/S

InventorsJan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Claims3

Dependent claims

A monoclonal antibody, or an epitope binding fragment thereof, comprising:

(a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:31;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:4;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:5;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:6;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:7;
and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:39.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/371,902Filed 1 Apr 2019 · division
Priority: DK 2016 0041612 Jul 2016
Published: US 2019/0284266 A119 Sep 2019
Granted: 12 May 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification29 codes

C07K 16/18
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from animals or humans
A61K 39/395
Medicinal preparations containing antigens or antibodies: antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 49/00
Preparations for testing in vivo
A61P 9/10
Drugs for disorders of the cardiovascular system: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary…

Family

Application15/645,442Parent of this division · filed 10 Jul 2017
US 2019/0284266 A1Pre-grant publication · published 19 Sep 2019
US 10,472,415 B2Related patent
US 2018/0016330 A1Published application
US 10,647,762 B2This patent

From the US filing history. Foreign family members aren’t listed.